Astellas Pharma Inc. Share Price OTC Markets
Stocks
ALPMY
US04623U1025
Pharmaceuticals
OTC Markets Traded|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13.73 USD | -4.79% |
|
+4.89% | +3.31% |
| 07-13 | Pfizer, Astellas Secure FDA Nod For Bladder Cancer Drug | MT |
| 07-10 | Health Care Down on Rotation Back to Tech - Health Care Roundup | DJ |
| Market Cap | 3,945B 25.03B 21.73B 20.22B 18.59B 35.11B 2,366B 35.68B 236B 93.49B 1,190B 94.12B 92.05B | P/E 2027 * |
11.5x | P/E 2028 * | 11.9x |
|---|---|---|---|---|---|
| Enterprise Value | 3,815B 24.2B 21.02B 19.55B 17.98B 33.95B 2,288B 34.5B 229B 90.41B 1,151B 91.01B 89.02B | EV / Sales 2027 * |
1.69x | EV / Sales 2028 * | 1.67x |
| Free-Float |
97.66% | Yield 2027 * |
3.65% | Yield 2028 * | 3.77% |
Last Transcript: Astellas Pharma Inc.
| 1 day | -4.79% | ||
| 1 week | +4.89% | ||
| Current month | +2.69% | ||
| 1 month | +2.69% | ||
| 3 months | -3.99% | ||
| 6 months | -0.94% | ||
| Current year | +3.31% |
| 1 week | 13.37 |  | 14.47 |
| 1 month | 13.03 | | 14.47 |
| Current year | 12.82 | | 17.35 |
| 1 year | 10.03 | | 17.35 |
| 3 years | 8.37 | | 17.35 |
| 5 years | 8.37 | | 18.18 |
| 10 years | 8.37 | | 18.46 |
| Manager | Title | Age | Since |
|---|---|---|---|
Naoki Okamura
CEO | Chief Executive Officer | 63 | 09/02/2023 |
Kitamura Atsushi
DFI | Director of Finance/CFO | 54 | 31/10/2023 |
Tatjana Dragovic
CMP | Compliance Officer | - | 31/03/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Kenji Yasukawa
CHM | Chairman | 66 | 09/02/2023 |
Naoki Okamura
BRD | Director/Board Member | 63 | 31/05/2019 |
| Director/Board Member | 58 | 31/05/2023 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -4.79% | +4.89% | - | - | 25.7B | |
| -0.53% | -3.12% | +51.15% | +150.58% | 1,030B | |
| +0.21% | -1.13% | +53.26% | +46.92% | 617B | |
| -2.51% | -2.33% | +32.56% | +66.35% | 455B | |
| +0.06% | +1.17% | +36.21% | +31.25% | 350B | |
| -0.14% | -0.83% | +33.24% | +40.28% | 299B | |
| -0.69% | -0.44% | +9.86% | +14.23% | 265B | |
| -7.37% | -4.31% | -5.69% | -41.99% | 225B | |
| -0.64% | +3.68% | +27.80% | +62.95% | 209B | |
| -0.82% | -0.50% | +13.46% | +69.41% | 163B | |
| Average | -1.23% | +4.83% | +27.98% | +48.89% | 401.41B | |
| Weighted average by Cap. | -0.27% | +4.87% | +36.61% | +70.85% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 2,260B 14.33B 12.45B 11.58B 10.65B 20.11B 1,355B 20.44B 135B 53.55B 682B 53.91B 52.73B | 2,079B 13.19B 11.45B 10.65B 9.8B 18.5B 1,247B 18.8B 125B 49.27B 627B 49.6B 48.51B |
| Net income | 343B 2.17B 1.89B 1.76B 1.61B 3.05B 205B 3.1B 20.53B 8.12B 103B 8.17B 7.99B | 331B 2.1B 1.82B 1.7B 1.56B 2.94B 198B 2.99B 19.83B 7.84B 99.82B 7.89B 7.72B |
| Net Debt | -130B -825M -717M -667M -613M -1.16B -78.01B -1.18B -7.8B -3.08B -39.25B -3.1B -3.04B | -472B -3B -2.6B -2.42B -2.23B -4.2B -283B -4.27B -28.31B -11.19B -143B -11.27B -11.02B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 31/07/26 | US$13.73 | -4.79% | 147,959 |
| 30/07/26 | US$14.42 | +3.37% | 124,999 |
| 29/07/26 | US$13.95 | +2.20% | 77,611 |
| 28/07/26 | US$13.65 | +1.78% | 130,246 |
| 27/07/26 | US$13.41 | +1.56% | 175,779 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 4503 Stock
- ALPMY Stock
Select your edition
All financial news and data tailored to specific country editions
